Dry eye disease in patients with Graft versus Host disease patients research hub

Phase IIB Clinical Trial to evaluate the efficacy and safety of Allogeneic Mesenchymal Stem Cell (MSC) eye injection treatment as therapy for Graft-versus-Host Disease (GvHD) refractory to conventional treatments

This study looks at a new eye injection for severe dry eye caused by Graft-versus-Host Disease (GvHD). It aims to see if an injection of special cells (stem cells) can improve eye comfort and health when other treatments haven't worked.